Sep 2, 2026LATEST SOURCED
other
Elucid brings plaque analysis to market
Investors undisclosed
Amount$55MValuationUndisclosed
← Company explorer
Captables
EL
COMPANY PROFILE
Elucid
Tracked in the Captables newsroom
Historical ranking valuationUndisclosedNo reviewed valuation record
Disclosed primary funding in this record
Not establishedSum of non-overlapping disclosed USD amounts in confirmed primary financing entries in this record, including separately labeled equity components; not verified lifetime funding. Excludes amounts already included in a later round, announced, reported, database-only, debt, secondary and unclassified events.
0 confirmed primary rounds with disclosed USD amounts · Record through 2026-11-01THE BUSINESS
Get to know Elucid.
Its FDA-cleared Plaque-IQ software measures the amount and composition of plaque in coronary and carotid arteries, including plaque types associated with higher risk. Elucid is pairing that product with BioIntegrated FFR-CT, a non-invasive analysis of how coronary disease affects blood flow. The second product is under FDA review and is intended to give clinicians a combined view of anatomy, plaque biology, and physiology inside one reporting workflow.
Business context from our coverage From coverage published Sep 4, 2026Valuation history
Valuations reported at the time of each round.
No dated financing valuation has passed into this record.
Funding history
Funding rounds, debt and other financing events.
1sourced event · record as of 2026-11-01
Headline association; not a reviewed issuer link. Unlinked article observations are not independently reconciled financing events. This is covered public-source history, not an exhaustive issuer ledger.
Financing participants
Investors, lenders and other parties named in funding announcements.
No named participant has been added to this company’s public financing record.
Ownership evidence
Opening ownership research…
Captables coverage
Deals / Captables
Elucid raises $55M to commercialize AI that reads cardiovascular plaque
Elucid turns routine CT angiography into measurements of arterial plaque and blood-flow risk for physicians; its Series D will fund commercialization and regulatory work.
Captables Newsroom · 58d ago